Tissue Regenix Group PLC Notice of allowance for US meniscus patent (8652X)
November 25 2014 - 3:16AM
UK Regulatory
TIDMTRX
RNS Number : 8652X
Tissue Regenix Group PLC
25 November 2014
Tissue Regenix Group Plc
Tissue Regenix receives notice of allowance for US meniscus
patent
YORK, 25 November 2014 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Group"), the regenerative medical devices
company, has received notification from the United States Patent
& Trademark Office (USPTO) that it will be granted a patent
covering its dCELL(R) meniscus.
Tissue Regenix is currently developing a process for
decellularising donated human meniscus, based on the porcine
dCELL(R) Meniscus, which is starting a regulatory human clinical
trial in the EU to secure a CE mark. Like the animal tissue product
this would be a piece of decellularised human meniscus for use in
partial meniscal replacement (which accounts for 80% of procedures)
rather than as a full transplant.
The global sports medicine market was estimated at $6.1bn in
2012 with CAGR growth of 4.4% driving it to $8.2bn in 2019.
Geographically, North America was said to account for the largest
share of the global market in 2012 at just under $2.5bn .
'Minimally manipulated' human tissues are designated as
transplants by the FDA and do not require approvals in the same way
as medical devices. This could see a decellularised human meniscus
launched in the US in the next two years.
Tissue Regenix's dCELL(R) meniscus will be used to repair damage
from 'tears' in the meniscus knee cartilage as a result of acute
injury such as sports injuries. Meniscal injuries affect around 1.5
million people per year in Europe and the US. The dCELL(R) meniscus
has the potential to address this unmet clinical need as there are
no implants available in the US at present.
This is the latest US patent covering the use of the dCELL(R)
decellularisation process and follows the announcement in May 2014
that a patent, related to tissue matrices for bladder implantation,
has been granted.
Antony Odell, CEO of Tissue Regenix commented: "This meniscus
patent marks an important step forward in our US strategy as it
defines our intellectual property for both human & animal
tissue meniscus products in the world's largest market for sports
medicine. It enables us to pursue, with confidence, the second
phase of the roll-out of the Group's US human tissue strategy
following the successful launch of DermaPure(TM) in June 2014."
Tissue Regenix has offices in the UK and US and is concentrated
on the global commercialisation of its dCELL(R) technology.
Sports Medicine Devices Market - Global Industry Analysis, Size,
Share, Growth Trends and Forecast, 2013-2019.
ENDS
For further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 207 6806550
Andrew Adie
Notes to Editors
About Tissue Regenix & dCELL(R)
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQKQDDOBDDNDB
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024